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Br J Pharmacol. 2019;1–12.Background and Purpose: Hydrogen sulfide (H2S)‐releasing agents are viewed as
potential antihypertensive drugs. Recently, natural isothiocyanates emerged as origi-
nal H2S‐donor agents. Among them, erucin, present in some edible cruciferous plants,
shows suitable H2S‐releasing properties and features of “druggability.” The aim of this
work was to investigate the erucin‐mediated release of H2S inside vascular cells, its
vasorelaxing effects, and activity on BP of normo and hypertensive animals.
Experimental Approach: Intracellular H2S‐release and the hyperpolarizing effect of
erucin were tested using fluorescent dye, in human aortic smooth muscle cells
(HASMCs). Its direct vasorelaxing effect and ability to inhibit noradrenaline‐induced
vasoconstriction were evaluated on endothelium‐intact or ‐denuded rat aortic rings.
Its vasodilator properties were tested in coronary arteries using Langendorff‐
perfused rat hearts. Finally, erucin's antihypertensive activity was evaluated in vivo
in normotensive and spontaneously hypertensive rats (SHRs) by recording systolic
BP using the tail‐cuff method.
Key Results: Erucin induced the release of H2S inside HASMCs. Moreover, erucin
hyperpolarized the membrane of HASMCs membrane in a concentration‐dependent
manner. It induced vasodilatation of rat aortic rings, in endothelium‐denuded vessels.
This effect was further improved by the presence of endothelial NO. When pre‐
incubated with rat aortic rings, erucin induced concentration‐dependent inhibition
of noradrenaline‐induced vasoconstriction. Erucin did not affect basal coronary flow
but restored the flow to normal in pre‐contracted coronary vessels. Finally, in vivo,
erucin decreased systolic BP in SHRs by about 25%, and restored the BP to values
observed in normotensive rats.
Conclusions and Implications: Erucin is an H2S donor endowed with vasorelaxing
and antihypertensive effects.ce calcium‐activated potassium channels; CF, coronary flow; DADS, diallyldisulfide; DiBac4(3), bisoxonol dye bis(1,3‐dibutylbarbituric
an aortic smooth muscle cells; L‐NAME, Nω‐nitro‐L‐arginine methyl ester; NA, noradrenaline; Psys, systolic blood pressure; SHR,
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FIGURE 1 Molecular structure of erucin
What is already known
• Hydrogen sulfide (H2S) donors are potential
antihypertensive drugs.
• Natural isothiocyanates are H2S donors.
What this study adds
• The natural isothiocyanate erucin releases H2S inside
vascular cells.
• Erucin evokes vasorelaxing and antihypertensive effects
mediated by H2S.
What is the clinical significance
• Erucin may represent an attractive drug candidate for the
treatment of hypertension.
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Hypertension is still the most widespread chronic disease, it is the
main cause of life‐threatening cardiovascular complications, such as
stroke, coronary artery disease, and heart failure, and it is the principal
risk factor for premature mortality worldwide. A further rise in preva-
lence of hypertension is expected, because of economic growth, life-
style, and increased life expectancy (Kumar, 2013). Nowadays, this
sneaky silent killer is estimated to be responsible for about 10 million
deaths every year (Achelrod, Wenzel, & Frey, 2015; Noubiap et al.,
2018). However, adequate control of correct levels of blood pressure
is associated with an effective reduction in complications and mortal-
ity (Sundström et al., 2015; Xie et al., 2016). Consistently, many phar-
macological targets useful for treating hypertension have been
identified and a huge number of drugs of proven efficacy and safety
is currently available. However, in spite of this wide and heteroge-
neous choice of pharmacological interventions, a significant number
of hypertensive patients cannot achieve blood pressure control (Myat,
Redwood, Qureshi, Spertus, & Williams, 2012; Pierdomenico et al.,
2005; Sarafidis, Georgianos, & Bakris, 2013). In particular, the preva-
lence of true resistant hypertension (i.e., the resistance that occurs in
fully adherent patients treated with well‐designed therapies and mul-
tiple antihypertensive drugs) is estimated to be about 10% (Noubiap
et al., 2018). Therefore, the discovery of original pharmacological
mechanisms and novel antihypertensive drug candidates is still a
timely and compelling issue.
Since the discovery of hydrogen sulfide (H2S) as an endogenous
gasotransmitter, the potential utility of this small gaseous molecule in
cardiovascular pharmacology has emerged (Bucci & Cirino, 2011;
Martelli et al., 2012). Indeed, H2S acts as a vasorelaxing mediator and
is a key regulator of vascular tone homeostasis (Gheibi, Jeddi, Kashfi,
& Ghasemi, 2018). In vascular tissues, physiological levels of this
gasotransmitter are mainly biosynthesized by cystathionine γ‐lyase
(CSE), although the contribution of the other two H2S‐generating
enzymes cystathionine β‐synthase (CBS) and 3‐mercaptopyruvate
sulfurtransferase (MPST) cannot be excluded (Yang & Wang, 2015).
An altered biosynthesis of H2S is presently known to account for
“H2S‐rich” or “H2S‐poor” diseases, associated with an excess or defi-
ciency of H2S respectively (Szabo & Papapetropoulos, 2017). In partic-
ular, H2S deficiency is likely to have a relevant significant role in
hypertension (Ahmad et al., 2015; Meng, Ma, Xie, Ferro, & Ji, 2015).
Indeed, an association between a deficiency in H2S and hypertension
has been clearly demonstrated in rodents (Yan, Du, & Tang, 2004; Yang
et al., 2008) and even in humans. In fact, reduced H2S concentrations
have been detected in plasma of grade 2 and 3 hypertensive patients
(Sun, Xi, Yang, Ma, & Tang, 2007), in patients with portal hypertension
(Wang et al., 2014) and in maternal hypertension and preeclampsia
(Wang et al., 2013). Conversely, the administration of exogenous H2S
by suitableH2S donors can be considered as a useful innovative strategy
for the pharmacological treatment of hypertension. Actually, different
chemotypes of H2S donors exhibited vasorelaxing activity and blood
pressure lowering effects in several scientific studies (Szabo &
Papapetropoulos, 2017). The importance of most of these compoundshas been to elucidate the molecular mechanism of action of H2S and
understand the pathophysiological roles of H2S in the regulation of car-
diovascular function. Nevertheless, for clinical applications an ideal H2S
donor should combine well‐balanced H2S‐releasing properties (in par-
ticular, slow and long‐lasting release) with other essential pharmacolog-
ical “druggability” features, such as good oral bioavailability, safety,
known biotransformation, and safe metabolites.
In a recent paper, we first reported the H2S‐releasing properties of
different natural isothiocyanates, which are phytochemical com-
pounds typical of cruciferous plants (family of Brassicaceae; Citi
et al., 2014). These properties were tested by “cell‐free” electrochem-
ical approaches, but no pharmacological evaluation of their cardiovas-
cular effects was carried out. Among the various isothiocyanates,
erucin seems to be worthy of pharmacological investigation, because
of its favourable characteristics. Indeed, erucin (Figure 1) showed slow
and long‐lasting release of H2S. Moreover, erucin is present in edible
plants, such as Eruca sativa Mill. (salad rocket), which are widely used
in human nutrition and are not associated with any evidence of toxic-
ity. Different pharmacokinetic studies on erucin have been carried out
in animals and humans. These studies demonstrated that erucin is well
absorbed after oral administration; they also described the metabolites
of erucin derived from its biotransformation (Clarke et al., 2011; Platz
et al., 2015).
The aim of this study was to evaluate the potential H2S‐releasing
activity of erucin in vascular smooth muscle, investigate its typical
H2S‐mediated effects in vascular smooth muscle cells and in isolated
vessels, and finally, assess the in vivo effects of erucin in a suitable
experimental model of hypertension.
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2.1 | Cell cultures
Human aortic smooth muscle cells (HASMCs, Cat.no: C‐007‐5C) were
purchased fromThermo Fisher (Waltham, MA, USA) and were cultured
following the manufacturer's instructions. Briefly, HASMCs were
cultured in Medium 231 (Thermo Fisher) supplemented with Smooth
Muscle Growth Supplement (Thermo Fisher), 1% of 100 units·ml−1
penicillin and 100 mg·ml−1 streptomycin (Sigma‐Aldrich, St. Louis,
MO, USA) in tissue culture flasks at 37°C in a humidified atmosphere
of 5% CO2. Cells were split 1:2 twice a week and used until passage 16.2.2 | Intracellular H2S‐release measurement
HASMCs were cultured up to about 90% confluence and 24 hr before
the experiment cells were seeded onto a 96‐well clear‐bottom black
plate, pre‐coated with gelatin 1% (from porcine skin, Sigma‐Aldrich),
at a density of 30 × 103 per well. After 24 hr, to allow cell
attachment, the medium was replaced and cells were incubated for
30 min with a 100 μM solution of the fluorescent dye WSP‐1
(Washington State Probe‐1,3′‐methoxy‐3‐oxo‐3H‐spiro[isobenzofur-
an‐1,9′‐xanthen]‐6′‐yl‐2(pyridin‐2‐yldisulfanyl benzoate); Cayman
Chemical, Ann Arbor, MI, USA). After the 30 min incubation of
HASMCs with WSP‐1 (allowing cells to up‐load the dye), the superna-
tant was removed and replaced with different solutions of erucin
(CREA, Bologna, Italy) dissolved in standard buffer (HEPES, 20 mM;
NaCl, 120 mM; KCl, 2 mM; CaCl2·2H2O, 2 mM; MgCl2·6H2O, 1 mM;
glucose, 5 mM; and pH 7.4, at room temperature) at three increasing
concentrations (30, 100, and 300 μM). WSP‐1 is a specific and highly
sensitive dye for H2S detection; indeed, when it reacts with H2S, it
releases a fluorophore detectable with a spectrofluorometer at
λ = 465–515 nm. The change in fluorescence (expressed as fluores-
cence index) was monitored every 5 min for 35 min, by means of an
EnSpire (PerkinElmer, Waltham, MA, USA) spectrofluorometer and it
was calculated as the difference between the fluorescence at time t,
after the addition of erucin or vehicle (DMSO 1%, Sigma‐Aldrich),
and the basal fluorescence. The AUC was also calculated. On the
bases of previous experiments (Barresi et al., 2017), diallyldisulfide
(DADS, Sigma‐Aldrich) 300 μMwas used as slow H2S‐donor reference
compound. Six different experiments (n = 6) were performed, each
carried out in six replicates. The results are expressed as mean ± SEM.2.3 | Evaluation of HASMC membrane
hyperpolarization
HASMCs were seeded onto a 96‐well black plate, clear‐bottom pre‐
coated with gelatin 1% (Sigma‐Aldrich), at density of 72 × 103 cells
per well. After 24 hr, the medium was replaced, and cells were
incubated for 1 hr with the bisoxonol dye bis(1,3‐dibutylbarbituric
acid) (DiBac4(3), 2.5 μM, Sigma‐Aldrich) dissolved in a standard buffer.
This membrane potential‐sensitive dye DiBac4(3) allowed us a non‐electrophysiological measurement of changes in cell membrane poten-
tial as already described (Martelli et al., 2014). An increase in fluores-
cence, due to an inward flow of the dye, is a consequence of
membrane depolarization; conversely, a decrease in fluorescence, con-
sequent to an outward flow of the dye, reflects membrane hyperpolar-
ization. The spectrofluorometric measurement was set at excitation
and emission wavelengths of 488 and 520 nm respectively (Multiwells
reader, Enspire, PerkinElmer). NS1619 (10 μM, Sigma‐Aldrich), a well‐
known activator of BKCa potassium channels, was used as a reference
hyperpolarizing drug. After the basal fluorescence had been measured,
cells were treated with different concentrations of erucin (30, 100,
and 300 μM), NS1619, or vehicle (DMSO 1%), and changes in
fluorescence were recorded for 35 min. The relative reduction in
fluorescence, consequent to membrane hyperpolarization, was
recorded every 2.5 min and was expressed as (Ft − F0)/F0, where
F0 represents the basal fluorescence and Ft is the fluorescence at time
t after the administration of the test compounds. Moreover, the AUC
was also calculated. The results were expressed as a % of the AUC
induced by NS1619 10 μM. Six different experiments (n = 6) were per-
formed, each carried out in six replicates.2.4 | Animal procedures and ethical statements
All the procedures involving animals were carried out following the
guidelines of the European Community Council Directive 86‐609
and in accordance with the Code of Ethics of the World
Medical Association (Declaration of Helsinki, EU Directive 2010/63/
EU for animal experiments). The experiments were authorized by the
Ethical Committee of the University of Pisa (Protocol number
0037321/2013) and by the Italian Ministry of Health (authorization
number 751/2018‐PR). All the animals were housed in humidity‐ and
temperature‐controlled rooms (22°C and 50%, respectively) with 12‐
hr light/dark cycles, water, and food availability ad libitum. Three
animals were housed in each cage. All efforts to reduce and minimize
the number of animals and their suffering were carried out. Animal
studies are reported in compliance with the ARRIVE guidelines
(Kilkenny, Browne, Cuthill, Emerson, & Altman, 2010) and with the
recommendations made by the British Journal of Pharmacology. A
randomization of animals between groups and treatments was carried
out. The investigators responsible for data analysis were blind to
which animals represent which treatments and controls.2.5 | Functional assays on aortic rings
Adult male normotensive Wistar rats (300–350 g, Envigo, Huntingdon,
UK, RGD Cat# 2312511, RRID:RGD_2312511) were given an over-
dose of sodium thiopental (100 mg·kg−1 i.p., Pentothal MSD,
Kenilworth, NJ, USA), killed by cervical dislocation and bled. Thoracic
aorta was rapidly excised and freed of extraneous tissues. When
required for the experimental procedures, the endothelial layer was
removed by gently rubbing the intimal surface of the aortae with a
hypodermic needle. The aorta was cut in 5‐mm‐wide rings which were
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Tyrode solution (NaCl, 136.8 mM; KCl, 2.95 mM; CaCl2·2H2O,
1.80 mM; MgSO4·7H2O, 1.05 mM; NaH2PO4·H2O, 0.41 mM;
NaHCO3, 11.9 mM; and glucose, 5.5 mM), thermostated at 37°C,
and continuously gassed with Clioxicarb, a mixture of O2 (95%) and
CO2 (5%). An isometric transducer (Grass FTO3, Harvard Apparatus,
Holliston, MA, USA), connected to a preamplifier (Buxco Electronics,
Troy, NY, USA) and with software for data acquisition (BIOPAC
Systems Inc., MP 100, Goleta, CA, USA), was used to record changes
in tension. After an equilibration period of 60 min, the endothelial
maintenance or removal were confirmed by the administration of
ACh (10 μM) to KCl (25 mM)‐precontracted vascular rings. As regards
the endothelium‐intact aortic rings, a relaxation ≥70% of the KCl‐
induced contraction was considered representative of a suitable
presence of functional endothelium; while, the rings, exhibiting a
relaxation <70%, were discarded. Conversely, for the endothelium‐
removed aortic rings, a relaxation <10% of the KCl‐induced contrac-
tion represented an acceptable lack of the endothelial layer; while,
the rings, showing a relaxation ≥10%, were discarded.
In the first set of experiments, designed to evaluate the direct
vasorelaxing activity of erucin, after about 45 min from the confirma-
tion of the endothelium presence/removal, the aortic rings were
contracted with KCl 25 mM and when the contraction had reached
a stable plateau, erucin was added cumulatively (100 nM–100 μM).
When required, the inhibitor of the biosynthesis of endothelial nitric
oxide (NO), Nω‐nitro‐L‐arginine methyl ester (L‐NAME; Sigma‐Aldrich)
100 μM, was added 20 min before KCl. Preliminary experiments dem-
onstrated that the KCl (25 mM)‐induced contractions remained in a
stable tonic state for at least 60 min. The maximal vasorelaxing effi-
cacy (Emax) was presented as the maximal vasorelaxing response
achieved with the highest concentration of erucin(100 μM) and
expressed as a percentage (%) of the contractile tone induced by
KCl. Potency is expressed as pEC50, calculated as negative logarithm
of the molar concentration of erucin evoking an effect = 50% of Emax.
The parameters for efficacy and potency are expressed as mean ± SEM,
from aortae of six animals (n = 6) for each different treatment.
In a separate set of experiments, the inhibition of noradrenaline
(NA)‐induced vasoconstriction by erucin was evaluated. In particular,
45 min after the confirmation of endothelium removal, the
endothelium‐denuded aortic rings were contracted with 60mM KCl,
as a reference depolarizing stimulus evoking an almost full contraction
of vascular smooth muscle. After a plateau state had been reached,
the preparations were washed, and after 45 min of re‐equilibration,
rings were exposed to different concentrations of erucin (10, 30, and
100 μM) or the corresponding vehicle (DMSO 1%) for 20 min. There-
after, a cumulative concentration–response curve for NA (1 nM–
1 μM) was performed. In order to rule out a potential toxic effect
and/or to test the viability of the vascular musculature and the
“reversibility” of the inhibitory effect of erucin, rings were extensively
washed. Then, the concentration–response curve to NA (1 nM–1 μM)
was repeated. NA concentration–vasocontraction response curves
were analysed by the Hill equation, and the efficacy of NA expressed
as maximal contractile response, calculated as a percentage (%) of thecontractile tone previously induced by 60 mM KCl. The parameter of
potency pE50, was calculated as the negative logarithm of the molar
concentration of NA evoking a half‐maximal response. The results
for the efficacy and potency of NA are expressed as mean ± SEM, of
six experiments (n = 6) for each different treatment.2.6 | Measurement of coronary flow
Adult male normotensive Wistar rats (300–350 g) were anaesthetized
with an overdose of sodium thiopental (100 mg·kg−1 i.p.); hearts were
quickly excised and placed in Krebs solution (NaHCO3, 25 mM; NaCl,
118.1 mM; KCl, 4.8 mM; MgSO4, 1.2 mM; CaCl2·2H2O, 1.6 mM;
KH2PO4, 1.2 mM; and glucose, 11.5 mM) at 4°C bubbled with
clioxicarb to stop the heart contracting and reduce oxygen consump-
tion. Then, the hearts were rapidly mounted in a Langendorff appara-
tus (Radnoti, Monrovia, USA) and perfused with Krebs solution gassed
with clioxicarb at 37°C at constant pressure (70–80 mmHg). Coronary
flow (CF) was volumetrically recorded every 5 min, expressed as
ml·min−1, and normalized to the heart weight (g). After a 20 min equil-
ibration period, some hearts were selected to determine the effects of
erucin on the basal flow: briefly, the hearts were perfused with Krebs
solution containing erucin at cumulatively increasing concentrations
(0.1, 1, 10, and 100 μM, for 20 min, each concentration). Another
set of experiments was dedicated to demonstrate the effects of erucin
on CF of hearts precontracted with angiotensin II (AngII). These hearts,
after the initial 20 min of equilibration, were perfused with AngII
0.1 μM, and at the onset of a stable coronary spasm (observed as a
reduction in the CF), cumulatively increasing concentrations of erucin
(0.1, 1, 10, and 100 μM, for 20 min, each concentration) were admin-
istered (in the constant presence of AngII 0.1 μM). Preliminary exper-
iments demonstrated that perfusion with AngII 0.1 μM caused a rapid
fall in the CF, stable for at least 2 hr. Changes in CF are expressed as
percentage (%) of the basal CF. Experiments were carried out on
hearts from six animals (n = 6) for each different treatment.2.7 | In vivo measurement of blood pressure on
normotensive and spontaneously hypertensive rats
The effects of erucin and its vehicle (DMSO 1 ml·kg−1) on BP were
tested on 12‐week‐old male normotensive (Wistar) and spontaneously
hypertensive rats (SHR; 300–350 g), which represents one of the best
models for essential hypertension. Briefly, rats were anaesthetized
with sodium thiopental 60 mg·kg−1 i.p. and after the administration
of the anaesthetic, they were kept on a heated platform (about
30°C) for 20 min to induce a slight vasodilatation of the tail artery,
in order to allow an easier recording of the basal systolic BP (Psys)
with the “tail‐cuff” method by a BP recorder (BP‐2000 Blood Pressure
Analysis System, Series II, Visitech System, Apex NC, USA). Basal level
of Psys was recorded for 20 min, at 5 min intervals. Then, erucin
10 mg·kg−1 or the corresponding vehicle were administered i.p. to dif-
ferent groups (normotensive vs. SHR), each composed of six rats.
Starting from the administration of the test compounds, the Psys
MARTELLI ET AL. 5BJPvalues were recorded, for 2 hr after 10, 30, 60, 90, and 120 min. Basal
Psys was expressed as a mean of the four measurements carried out in
each rat before the administration of test compounds. Change in Psys,
recorded after erucin or vehicle administration, is expressed as a
percentage of the basal Psys and also calculated as mean value of
the five recordings (at 10, 30, 60, 90, and 120 min) carried out
after drug administration. BP measurements were carried out in six
animals per group (n = 6 for each treatment both in normotensive
and SHR groups).2.8 | Data and statistical analysis
All the experimental data were analysed by a computer fitting proce-
dure (GraphPad Prism 6.0, La Jolla, CA, USA, RRID:SCR_002798) and
expressed as mean ± SEM of at least six independent experiments.
All the group sizes were designed to be homogeneous. ANOVA and
Student's t‐test were selected as statistical analyses. When required,
the Bonferroni post hoc test was used. P < 0.05 was considered rep-
resentative of significant statistical differences. The data and statistical
analysis comply with the recommendations of the British Journal of
Pharmacology on experimental design and analysis in pharmacology.2.9 | Materials
Cell culture reagents Medium 231 (Cat.no.: M‐231‐500) and Smooth
Muscle Growth Supplement (Cat.no.: S‐007‐25) were from Thermo
Fisher while penicillin/streptomycin solution (Cat.no.: P4333), gelatin
(Cat.no.: G1890, CAS Number: 9000‐70‐8), DADS (Cat.no.:
SMB00378, CAS Number: 2179‐57‐9), DMSO (Cat.no.: D 2650, CAS
Number: 67‐68‐5), DiBac4(3) (Cat.no: D8189, CAS Number: 70363‐
83‐6), NS1619 (Cat.no.: N170, CAS Number: 153587‐01‐0), ACh
chloride (Cat.no: A9101, CAS Number: 60‐31‐1), KCl (Cat.no.:
P9333, CAS Number: 7447‐40‐7), L‐NAME (Cat.no.: N5751, CAS
Number 51298‐62‐5), NA hydrochloride (Cat.no: A7256, CAS Number
55‐27‐6), AngII (Cat.no.: A9525, CAS Number 4474‐91‐3), and all the
salts and glucose (Cat.no.: G8270, CAS Number 50‐99‐7) used for
preparation of Buffer standard, Tyrode, and Krebs solutions were from
Sigma‐Aldrich. WSP‐1 (Cat.no.: 11179, CAS Number: 1352750‐34‐5)
was from Cayman Chem. Purified erucin (CAS Number: 4430‐36‐8)
was kindly provided by the Italian Council for Agricultural Research
and Economics, Research Centre for Cereal and Industrial Crops
(Bologna, Italy).2.10 | Nomenclature of targets and ligands
Key protein targets and ligands in this article are hyperlinked to
corresponding entries in http://www.guidetopharmacology.org, the
common portal for data from the IUPHAR/BPS Guide to PHARMA-
COLOGY (Harding et al., 2018), and are permanently archived in the
Concise Guide to PHARMACOLOGY 2017/18 (Alexander, Fabbro
et al., 2017; Alexander, Striessnig et al., 2017).3 | RESULTS
3.1 | Erucin exhibits intracellular H2S‐release in
HASMCs
Erucin was able to release H2S inside cells. Indeed, the addition of
several concentrations of erucin to HASMCs caused a significant,
gradual, and concentration‐dependent increase in WSP‐1 fluores-
cence (indicating the generation of intracellular H2S), until the reaching
of a plateau, (Figure 2a). The AUC of the H2S‐release was also
calculated and highlighted a clear concentration‐dependent release.
The amount of H2S released from the highest concentration of erucin
(300 μM) reached about 70% of the value obtained after the adminis-
tration of the reference H2S‐donor DADS (300 μM; Figure 2b).3.2 | Hyperpolarizing effect of erucin on HASMC
membrane
The hyperpolarizing effect of erucin on HASMCs pre‐incubated with
DiBac4(3) was recorded for 35 min until a plateau was obtained, and
compared with the effect of a well‐known hyperpolarizing drug, that
is, the BKCa activator, NS1619 10 μM (Figure 3a). As shown in
Figure 3a and in the correlated AUC graph (Figure 3b), the hyperpolar-
izing effect of erucin on HASMC membrane was significant versus
vehicle, concentration‐dependent and, at the highest concentration
(300 μM), it was also comparable (106 ± 2% of the NS1619 hyperpo-
larizing effect) with that of the reference drug, confirming that the
novel H2S‐donor erucin is a hyperpolarizing drug.3.3 | Direct vasorelaxing effect on rat aortic rings
Erucin evoked endothelium‐independent vasorelaxing effects, since it
caused vasodilatation of endothelium‐denuded rat aortic rings precon-
tracted with KCl (Emax = 35 ± 6%; pEC50 = 4.95 ± 0.07). However,
this vasorelaxing effect was significantly increased when erucin was
tested on endothelium‐intact rat aortic rings precontracted with KCl
(Emax = 56 ± 4%; pEC50 = 5.63 ± 0.08). In order to confirm a possible
influence of the endothelial function on the vasorelaxing effect of
erucin, its vascular effects were also evaluated in endothelium‐intact
rat aortic rings pre‐incubated with L‐NAME 100 μM, an inhibitor of
endothelial NOS (eNOS) biosynthesis. The experiments performed in
the presence of L‐NAME showed a reduction in the maximal
vasorelaxing effect (Emax = 26 ± 7; pEC50 = 5.27 ± 0.11) leading to
a curve being obtained that was almost superimposable on the curve
produced by erucin in endothelium‐denuded rat aortic rings
(Figure 4).3.4 | Inhibition of NA‐induced vasoconstriction
Besides its direct vasodilating effect, erucin also inhibited the NA‐
evoked vasoconstriction. In the vehicle pretreated endothelium‐
denuded aortic rings, NA induced a sustained vasoconstriction, with
FIGURE 2 Fluorometric recording of erucin‐mediated H2S‐release inside HASMCs. (a) Time course of the fluorometric recordings of
H2S released by vehicle, erucin 30, 100, and 300 μM and DADS 300 μM, during 35 min of observation: the increase in H2S is expressed as FI.
(b) The histograms show the total amount of H2S released by vehicle, erucin 30, 100, and 300 μM and DADS 300 μM, in the 35 min of
observation time, expressed as AUC. The vertical bars represent SEM, six different experiments were performed, each with six replicates (n = 6).
The asterisks indicate a statistically significant difference from vehicle (*P < 0.05)
FIGURE 3 Hyperpolarizing effects in HASMCs. (a) Time‐course spectrofluorometric recording of changes in HASMCs membrane potential,
followed for 35 min, expressed as (Ft − F0)/F0 and induced by vehicle, erucin 30, 100, and 300 μM and the hyperpolarizing reference drug,
NS1619 10 μM. (b) Corresponding AUC of the hyperpolarizing effect of vehicle, erucin 30, 100, and 300 μM and NS1619 10 μM. Data are
expressed as mean ± SEM. Six different experiments were performed, each with six replicates (n = 6). The asterisks indicate a significant difference
from the effect evoked by vehicle (*P < 0.05)
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treatment with increasing concentrations of erucin (10, 30, and
100 μM) caused a progressive inhibition of both the potency and effi-
cacy of NA. Indeed, pre‐incubation of the aortic rings with erucin (10,
30, and 100 μM) led to concentration‐dependent and significant inhib-
itory effects. In particular, the increasing concentrations of erucin pro-
duced a similar reduction in the efficacy of NA by about 25–30%, but
different effects on NA potency (pEC50) of 7.20 ± 0.10, 6.94 ± 0.06,
and 6.69 ± 0.04, for erucin 10, 30, and 100 μM respectively
(Figure 5a). Noteworthy, the inhibitory effect of erucin at the different
concentrations was fully reversible; indeed, after an organ washout, a
full recovery of the contractile effects of NA was observed (Figure 5b).3.5 | Evaluation of the functional effects on the CF
The basal CF in Langendorff‐perfused rat hearts was
13.08 ± 1.92 ml·min−1·g−1. The administration of 0.1, 1, 10, and 100μM erucin did not affect the basal values of CF (Figure 6a). A different
trend was observed when AngII (0.1 μM) was administered to the rat
hearts. Indeed, in the presence of AngII, the CF was significantly
reduced to 81.8 ± 3.3% of the basal value, and the administration of
0.1, 1, 10, and 100 μM erucin, in the continuous presence of AngII,
led to a progressive increase in CF, which was finally restored to the
basal CF value, when 100 μM erucin was added (101.9 ± 4.1% of
the CF basal value; Figure 6b).3.6 | Effect of erucin on systolic BP in SHR and
normotensive rats
On the basis of previous results obtained in vascular smooth
muscle, in vivo BP measurements have been carried out in SHR and
normotensive rats. Normotensive Wistar rats showed basal Psys of
133 ± 2 mmHg, and i.p. administration of vehicle did not alter the
basal Psys value. The administration of erucin 10 mg·kg−1 i.p. caused
FIGURE 4 Direct vasorelaxing effects. Concentration–response
curves, relative to the vasorelaxing effects evoked by erucin, in
endothelium‐intact and ‐denuded rat aortic rings, precontracted with
KCl 25 mM. In endothelium‐intact aortic rings, the vasorelaxing
effects have been recorded either in the absence or presence of L‐
NAME 100 μM (inhibitor of the NO‐biosynthesis). The vertical bars
indicate the SEM. Six different experiments were performed, each
with six replicates (n = 6). The asterisks indicate a significant
difference from the curve obtained on endothelium‐intact aortic
rings (*P < 0.05)
FIGURE 5 Inhibition of NA‐induced vasoconstriction.
(a) Concentration–response curves to NA, obtained in endothelium‐
denuded rat aortic rings pre‐incubated with vehicle or erucin at the
concentrations of 10, 30, and 100 μM. The effects are expressed as a
% of the contractile responses previously induced by the
administration of KCl 60 mM. The vertical bars indicate the SEM. Six
different experiments were performed, each with six replicates (n = 6).
The asterisks indicate a significant difference from the NA‐induced
vasoconstriction curve obtained on endothelium‐denuded aortic rings
pre‐incubated with the vehicle (*P < 0.05). (b) Representative
microdynamometric tracings obtained in two different aortic rings,
demonstrating that the inhibitory effects of erucin were fully
reversible. In the upper panel, one aortic ring was pre‐incubated with
vehicle (20 min); thereafter, cumulative increasing concentrations of
NA, evoking concentration‐dependent vasoconstriction, were added.
The aortic ring was submitted to washout (W) and adequate
MARTELLI ET AL. 7BJPonly a slight decrease in Psys, which was significantly different from
the vehicle at three recording times (10, 30, and 120 min; Figure 7a).
However, the overall mean change in Psys was not significant
(−9.98 ± 6.2%; Figure 7c). This behaviour was completely different
when erucin and vehicle were administered into SHRs. Indeed, SHRs
exhibited basal Psys of 177 ± 3 mmHg and, as already observed for
normotensive rats, the i.p. administration of vehicle did not alter the
basal Psys. In contrast, the administration of erucin 10 mg·kg−1 i.p.
to SHRs caused a clear and significant decrease in Psys both in the
curve of time recordings and in the bars reporting the overall mean
change in Psys (−23.9 ± 3.8%; Figure 7b,c).equilibration time to recover again the resting tension. Then, the aortic
ring was treated again with vehicle (20 min); thereafter, cumulative
increasing concentrations of NA, evoking concentration‐dependent
vasoconstriction, were added again. In the lower panel, the other
aortic ring was pre‐incubated with erucin 100 μM (the highest
concentration, for 20 min); thereafter, cumulative increasing
concentrations of NA, evoking reduced concentration‐dependent
vasoconstriction, were added. The ring was submitted to washout (W)
and an adequate equilibration time to recover again the resting
tension. Finally, the aortic ring was treated with vehicle (20 min);
thereafter, cumulative increasing concentrations of NA, evoking
concentration‐dependent vasoconstriction, were added again. In the
lower panel, complete recovery of the vasoconstriction effects of NA
is evident4 | DISCUSSION
After it was discovered that H2S has multiple pathophysiological
roles and the potential therapeutic application of H2S‐donor drugs
in “H2S‐poor” pathologies was realized, much effort has been
devoted to the characterization of new H2S‐releasing chemical moi-
eties. In this broad panorama of heterogeneous chemical structures,
we identified the isothiocyanate group as an interesting moiety.
Indeed, in previous studies, we found that some synthetic aryl‐
isothiocyanates behaved as H2S donors and caused clear H2S‐medi-
ated vasorelaxing effects. Noteworthy, the release of H2S from
these aryl‐isothiocyanates was not a spontaneous process but was
triggered by the presence of organic thiols (e.g., L‐cysteine or
GSH), as often documented for other classes of H2S donors, such
as allyl polysulfides (Benavides et al., 2007), thioamides (Martelli,
Testai, Citi, et al., 2013), iminotioethers (Barresi et al., 2017), or
GYY4137 (one of the best characterized H2S donors; Martelli, Testai,
Citi, et al., 2013). This thiol‐dependent profile was considered as auseful feature of a “smart” H2S donor (Calderone, Martelli, Testai,
Citi, & Breschi, 2016), as it would ensure that the release of H2S
does not occur spontaneously and in an undifferentiated way but
is particularly facilitated in just the cell cytosol, where the highest
concentrations of organic thiols are present: GSH (in 1–10 mM
range) and cysteine (in 30–200 μM range; Tian et al., 2014)
FIGURE 6 Effects on coronary flow. Changes in CF (expressed as a % of the basal CF) induced by the perfusion of increasing concentrations of
erucin, in the absence (a) or in the constant presence (b) of AngII, as a co‐administration. The vertical bars indicate the SEM. Six different
experiments were performed, (n = 6). The asterisks indicate a significant difference from the basal CF (*P < 0.05) while the symbols §indicate a
significant difference from the CF recorded in the presence of AngII 0.1 μM (§P < 0.05)
FIGURE 7 Effects on blood pressure. Time‐course of changes in systolic blood pressure values, expressed in mmHg in normotensive (a) and SHR
rats (b) after i.p. administration of vehicle (DMSO 1 ml·kg−1) or erucin 10 mg·kg−1, recorded for 2 hr, at 10, 30, 60, 90, and 120 min. The vertical
bars indicate the SEM. Six different experiments were performed for each treatment (n = 6). The asterisks indicate a significant difference from
Psys trend curve obtained after the administration of vehicle (*P < 0.05). Overall mean change in Psys (expressed as a % of the basal Psys values) in
normotensive (c) and SHRs (d), recorded in the 2 hr after i.p. administration of vehicle (DMSO 1 ml·kg−1) or erucin 10 mg·kg−1. The vertical bars
indicate the SEM. Six different experiments were performed for each treatment (n = 6). The asterisks indicate a significant difference from changes
in Psys (%) obtained after the administration of vehicle (*P < 0.05)
8 MARTELLI ET AL.BJPIn this context, we have previously demonstrated that erucin, a
natural isothiocyanate, typically present in many edible cruciferous
plants, behaved as a smart H2S donor, since it exhibited slow, long‐
lasting, and thiol‐dependent release of H2S; however, this result was
obtained in a “cell‐free” experimental model in vitro (Citi et al.,
2014). Therefore, the first objective of this work was to test the ability
of erucin to enter vascular smooth muscle cells and promote the gen-
eration of H2S using the intracellular pool of organic thiols. DADS was
used as a reference H2S donor for this experiment, since it sharessome physicochemical analogies with erucin (relatively low molecular
weight, no charge, lipophilicity). In contrast, the use of other well‐
known H2S donors, such as the inorganic sulfides, did not seem to
be appropriate, because of the large differences in terms of physico-
chemical properties and of H2S‐releasing rates. As detected by the
spectrofluorimetric assay with the WSP‐1 probe, the incubation of
HASMCs with erucin promoted a slow and progressive increase in
H2S levels, in a concentration‐dependent way. In particular, incubation
with the highest concentration of erucin (300 μM) led to an
MARTELLI ET AL. 9BJPintracellular production of H2S which was about 75% of that produced
by an equimolar concentration of DADS. However, it should be noted
that the functional group isothiocyanate can release a single H2S mol-
ecule; instead, DADS generates two H2S molecules, as elegantly dem-
onstrated by Benavides et al. (2007).
Next, we evaluated whether erucin evoked typical H2S‐mediated
vascular responses. As reported above, H2S is a pivotal regulator of
vascular tone, through its vasorelaxing effect. Indeed, by means of
“S‐sulfhydration,” that is, the post‐translational modification of cyste-
ine residues of target proteins (Paul & Snyder, 2012), H2S promotes
multiple mechanisms of action responsible for its vasodilator activity,
against the vasoconstrictor effects evoked by different stimuli, which
were either receptor‐mediated or non‐receptor‐mediated. Among
them, the modulation of several types of vascular potassium channel,
with consequent membrane hyperpolarization in vascular smooth
muscle cells, plays a relevant role. For instance, H2S‐mediated vasore-
laxation was very early attributed to the activation of vascular ATP‐
sensitive potassium channels (Kir6.2) (Zhao, Zhang, & Lu, 2001). In
addition, the activation of Kv7 voltage gated potassium channels
has been more recently proposed as a further important and peculiar
mechanism accounting for the vasorelaxing effects of H2S (Martelli,
Testai, Breschi, et al., 2013; Schleifenbaum et al., 2010). Therefore,
we decided to evaluate the effects produced by erucin on the mem-
brane potential of HASMCs cells. In this kind of experiment, NS1619
was selected as a reference drug, because it is a powerful activator
of vascular large‐conductance calcium‐activated potassium channels
(KCa1.1), which can promote a massive hyperpolarization of the cell
membrane (Calderone, 2002). Through the potential‐sensitive probe
DiBac4(3), it was shown that erucin causes a concentration‐dependent
membrane hyperpolarization in HASMCs, thus exhibiting typical H2S‐
mediated vascular effects. Noteworthy, the hyperpolarizing effects
produced by the highest concentration of erucin (300 μM) were
equivalent to those produced by the reference drug. The identification
of the specific potassium channel type(s) involved in this hyperpolariz-
ing effect will be the object of future electrophysiological studies.
Concerning the H2S‐mediated functional effects, erucin exhibited
endothelium‐independent vasorelaxing activity, since it evoked
concentration‐dependent vasorelaxation of endothelium‐denuded
aortic rings. The vasorelaxing effects were further increased when
erucin was administered to endothelium‐intact rat aortic rings. How-
ever, when erucin was added to endothelium‐intact rat aortic rings
pretreated with L‐NAME (inhibitor of eNOS), the vasorelaxing effects
were almost equivalent to those recorded in the endothelium‐
denuded vessels. Thus, the H2S‐mediated vasorelaxing effect of erucin
is endothelium‐independent but is significantly improved by the pres-
ence of endothelium and in particular by the presence of endothelial
NO. Indeed, data on the possible interactions between H2S and NO
are numerous and sometimes conflicting (Cirino, Vellecco, & Bucci,
2017; Nagpure & Bian, 2016). However, it is currently accepted that
the overall interplay between the two gasotransmitters (at physiolog-
ical concentrations) is positive and acts through multiple mechanisms,
such as the formation of active hybrid species, the H2S‐induced mobi-
lization of NO from stable “pools,” the increased activity of eNOSthrough calcium mobilization and PI3K/Akt signalling, and the syner-
gistic effects on cGMP (NO activates the guanylate cyclase, while
H2S inhibits PDE5 and activates cGMP‐dependent protein kinases;
Szabo, 2016). Alongside its direct vasodilator effects, erucin signifi-
cantly inhibited the vasoconstriction induced by the adrenoceptor
agonist NA on endothelium‐denuded rat aortic rings. Noteworthy,
these effects were reversible, confirming the involvement of pharma-
cological mechanisms of action, rather than possible tissue damage
induced by toxicity.
The role of endogenous H2S in the physiological regulation of CF is
still an underdeveloped field of research. Recent experimental findings
indicate that endogenous H2S may have a modest role in
regulating canine coronary microvascular resistance (Casalini et al.,
2014), while the presence of H2S‐producing enzymes (in particular,
mercaptopyruvate sulfotransferase) was observed in rodent coronary
arteries (Kuo et al., 2016). However, irrespective of the potential role
of endogenous H2S, in the above experimental studies, the administra-
tion of exogenous H2S donors always caused a reduction in vascular
resistance and a significant increase in CF. This feature had been
observed previously for synthetic aryl‐isothiocyanate H2S donors
(Martelli et al., 2014; Testai et al., 2015). These effects suggest a pos-
sible utility for H2S donors in coronary artery diseases. In the present
study, the possible vasorelaxing effects of erucin were also confirmed
in the coronary arteries. The perfusion with erucin did not change the
flow of coronary arteries with a basal vascular tone, since the vascular
smooth muscle of these vessels is likely to be already relaxed. In con-
trast, when the coronary vessels were precontracted with AngII,
erucin promoted a significant increase in the flow in concentration‐
dependent fashion, bringing it back to baseline levels.
Although there is a paucity of data on H2S and human hyperten-
sion, many experimental studies indicate that an increase in H2S levels
induced by suitable H2S donors may be a rational and effective thera-
peutic approach for hypertensive patients (Van Goor, van den Born,
Hillebrands, & Joles, 2016). Indeed, different chemotypes of H2S
donors exhibit antihypertensive effects in different experimental
models of hypertension. For instance, early on it was observed that
administration of the well‐known H2S‐donor GYY4137 caused a
marked decrease in Psys in SHRs, while it caused lower (albeit signifi-
cant) hypotensive effects in normotensive animals (Li et al., 2008).
Sodium hydrosulfide (rapid H2S donor) has also been shown to exhibit
antihypertensive effects in SHRs (Ahmad et al., 2012). Novel H2S‐
donor iminothioethers have been recently reported to cause a signifi-
cant reduction in Psys in a rat experimental model of hypertension,
induced by pharmacological inhibition of eNOS (Barresi et al., 2017).
Therefore, in order to translate the above experimental observations
towards a reliable experimental model of pathology and therefore to
identify a possible clinical application of erucin, in the last step of this
study we evaluated the effects of erucin on the arterial pressure of
normotensive and hypertensive rats. In normotensive animals, inhibi-
tors of H2S biosynthesis are known to increase BP (Yan et al., 2004),
suggesting that the vascular regulatory mechanisms are fully activated
by endogenous H2S. Consistently, in our study, erucin had only a neg-
ligible influence on the BP of normotensive rats. In contrast, the
10 MARTELLI ET AL.BJPexpression/activity of H2S‐producing enzymes is significantly reduced
in SHRs and thus the H2S‐mediated regulatory mechanisms are
defective (Bucci et al., 2014; Yan et al., 2004). Noteworthy, in SHRs,
the administration of erucin (i.e., the H2S supplementation with this
H2S donor) caused a marked reduction in Psys, bringing it back to
the normotensive levels.5 | CONCLUSIONS
The isothiocyanate erucin is naturally present in some edible crucifer-
ous plants, commonly used in human nutrition and in functional diets,
and this would exclude serious toxicity concerns. Several studies have
already examined the main pharmacokinetic characteristics of erucin,
highlighting its appreciable oral bioavailability and providing a detailed
description of its metabolites. In these studies, no significant toxicity
of erucin or erucin‐derived metabolites has been reported. In the pres-
ent study, we demonstrated for the first time that erucin can be con-
sidered as an original H2S donor, with interesting vascular effects and,
in particular, with significant BP lowering effects in hypertensive ani-
mals and negligible effects in normotensive ones. Therefore, an ade-
quate pharmaceutical development of erucin or of improved erucin
analogues may actually pave the way for a new class of H2S‐donor
antihypertensive drugs, with reliable “druggability” and thus with the
real possibility of clinical use.
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